SCHEMBL1342996

SCHEMBL1342996

Cc1ccc(NC(=O)CC(=O)Nc2nc(CNS(C)(=O)=O)c(Cl)s2)c(C(=O)C2CCCC2)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.37
ACP1 P24666 1/20 0.37
PIK3CD O00329 1/20 0.35
PIK3CG P48736 1/20 0.35
ALDH1A1 P00352 2/20 0.35
ABCC1 P33527 1/20 0.34
CLK1 P49759 1/20 0.34
KMT2A Q03164 5/20 0.34
MEN1 O00255 4/20 0.34
RORC P51449 1/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
PI4KB Q9UBF8 1/20 0.33
LMNA P02545 1/20 0.33
CSNK1D P48730 1/20 0.33
THRB P10828 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341933 0.92 PIK3CD (0.36) MAPTACP1PIK3CDPIK3CGABCC1
SCHEMBL1341075 0.92 PIK3CD (0.36) MAPTACP1PIK3CDPIK3CGALDH1A1
SCHEMBL1343540 0.91 MAPT (0.38) MAPTACP1ALDH1A1ABCC1CLK1
SCHEMBL1342521 0.90 NPC1 (0.38) MAPTACP1ALDH1A1ABCC1CLK1
SCHEMBL1343137 0.90 RORC (0.39) ALDH1A1CLK1KMT2AMEN1RORC
SCHEMBL1342536 0.89 MAPT (0.37) MAPTACP1ALDH1A1ABCC1CLK1
SCHEMBL1342768 0.86 GCK (0.40) MAPTACP1ABCC1KMT2AMEN1
SCHEMBL1341829 0.84 IDH2 (0.36) MAPTPIK3CDPIK3CGALDH1A1CLK1
SCHEMBL2649976 0.84 RORC (0.36) ALDH1A1RORCNPC1RAB9API4KB
SCHEMBL1342958 0.83 MAPT (0.37) MAPTACP1ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 MAPT 2678/4885ACP1 2046/4885PIK3CD 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.